Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

864 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Hillmen P, et al. Among authors: socie g. Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617322 Free PMC article. Clinical Trial.
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socié G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Hillmen P, et al. Among authors: socie g. Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16. Blood. 2007. PMID: 17702897 Free article. Clinical Trial.
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
Schubert J, Hillmen P, Röth A, Young NS, Elebute MO, Szer J, Gianfaldoni G, Socié G, Browne P, Geller R, Rother RP, Muus P; TRIUMPH Study Investigators. Schubert J, et al. Among authors: socie g. Br J Haematol. 2008 Jun;142(2):263-72. doi: 10.1111/j.1365-2141.2008.07183.x. Epub 2008 May 22. Br J Haematol. 2008. PMID: 18503589 Free PMC article. Clinical Trial.
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P. Schrezenmeier H, et al. Among authors: socie g. Haematologica. 2014 May;99(5):922-9. doi: 10.3324/haematol.2013.093161. Epub 2014 Jan 31. Haematologica. 2014. PMID: 24488565 Free PMC article.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. Among authors: socie g. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G. Hillmen P, et al. Among authors: socie g. Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280. Am J Hematol. 2016. PMID: 26690023 Free article. No abstract available.
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S, Halter J, Gupta V, Bacigalupo A, Sociè G, Tichelli A, Schrezenmeier H, Marsh J, Passweg J, Rotoli B; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Risitano AM, et al. Among authors: socie g. Br J Haematol. 2010 Mar;148(5):791-6. doi: 10.1111/j.1365-2141.2009.08027.x. Epub 2009 Dec 7. Br J Haematol. 2010. PMID: 19995389 Free article. Clinical Trial.
Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.
Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, Gibson B, Vora AJ, Steward CG, Ewins AM, Hough RE, de la Fuente J, Velangi M, Amrolia PJ, Skinner R, Bacigalupo A, Risitano AM, Socie G, Peffault de Latour R, Passweg J, Rovo A, Tichelli A, Schrezenmeier H, Hochsmann B, Bader P, van Biezen A, Aljurf MD, Kulasekararaj A, Marsh JC, Samarasinghe S. Dufour C, et al. Among authors: socie g. Br J Haematol. 2015 Nov;171(4):585-94. doi: 10.1111/bjh.13614. Epub 2015 Jul 28. Br J Haematol. 2015. PMID: 26223288 Free article.
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Rondelli T, Risitano AM, Peffault de Latour R, Sica M, Peruzzi B, Ricci P, Barcellini W, Iori AP, Boschetti C, Valle V, Frémeaux-Bacchi V, De Angioletti M, Socie G, Luzzatto L, Notaro R. Rondelli T, et al. Among authors: socie g. Haematologica. 2014 Feb;99(2):262-6. doi: 10.3324/haematol.2013.090001. Epub 2013 Sep 13. Haematologica. 2014. PMID: 24038027 Free PMC article. Clinical Trial.
864 results